EA201201321A1 - Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний - Google Patents
Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеванийInfo
- Publication number
- EA201201321A1 EA201201321A1 EA201201321A EA201201321A EA201201321A1 EA 201201321 A1 EA201201321 A1 EA 201201321A1 EA 201201321 A EA201201321 A EA 201201321A EA 201201321 A EA201201321 A EA 201201321A EA 201201321 A1 EA201201321 A1 EA 201201321A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compounds
- diseases
- cystein
- infectious
- respiratory
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 108010028921 Lipopeptides Proteins 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 title 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 title 1
- 230000002458 infectious effect Effects 0.000 title 1
- 230000002757 inflammatory effect Effects 0.000 title 1
- 230000000241 respiratory effect Effects 0.000 title 1
- OEDPHAKKZGDBEV-GFPBKZJXSA-N (2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2r)-3-[2,3-di(hexadecanoyloxy)propylsulfanyl]-2-(hexadecanoylamino)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)CCCCCCCCCCCCCCC)CSCC(COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC OEDPHAKKZGDBEV-GFPBKZJXSA-N 0.000 abstract 1
- 102000002689 Toll-like receptor Human genes 0.000 abstract 1
- 108020000411 Toll-like receptor Proteins 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Toxicology (AREA)
- AIDS & HIV (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
Abstract
В заявке описан новый класс соединений, таких как липопептиды типа Pam3CSK4, иммуногенные композиции и фармацевтические композиции, содержащие такие соединения, и способы применения таких соединений для лечения или предупреждения заболеваний или нарушений, ассоциированных с Толл-подобными рецепторами типа 2. Согласно одному из объектов изобретения соединения можно применять в качестве адъювантов для повышения эффективности вакцины.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31655110P | 2010-03-23 | 2010-03-23 | |
PCT/US2011/029661 WO2011119759A1 (en) | 2010-03-23 | 2011-03-23 | Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc. |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201201321A1 true EA201201321A1 (ru) | 2013-04-30 |
EA023725B1 EA023725B1 (ru) | 2016-07-29 |
Family
ID=43982260
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201201321A EA023725B1 (ru) | 2010-03-23 | 2011-03-23 | Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний |
EA201501033A EA031379B1 (ru) | 2010-03-23 | 2011-03-23 | Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201501033A EA031379B1 (ru) | 2010-03-23 | 2011-03-23 | Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний |
Country Status (10)
Country | Link |
---|---|
US (2) | US8808703B2 (ru) |
EP (1) | EP2549990A1 (ru) |
JP (1) | JP5848748B2 (ru) |
KR (1) | KR101853513B1 (ru) |
CN (1) | CN102905703B (ru) |
AU (1) | AU2011232421B2 (ru) |
CA (1) | CA2792938C (ru) |
EA (2) | EA023725B1 (ru) |
MX (1) | MX341395B (ru) |
WO (1) | WO2011119759A1 (ru) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2012002723A (es) | 2009-09-02 | 2012-04-11 | Novartis Ag | Composiciones inmunogenicas que incluyen moduladores de la actividad de receptores tipo toll. |
US20120177681A1 (en) * | 2010-09-01 | 2012-07-12 | Manmohan Singh | Formulation of immunopotentiators |
ES2735274T3 (es) | 2010-09-22 | 2019-12-17 | Ena Therapeutics Pty Ltd | Nuevo método inmunoestimulador |
RU2013144207A (ru) | 2011-03-02 | 2015-04-10 | Новартис Аг | Комбинированные вакцины с пониженными дозами антигена и/или адъюванта |
EP2502631A1 (en) * | 2011-03-22 | 2012-09-26 | Medizinische Hochschule Hannover | Immune suppressor and its use |
KR20140066212A (ko) | 2011-09-01 | 2014-05-30 | 노파르티스 아게 | 스타필로코쿠스 아우레우스 항원의 보조제 첨가된 조제물 |
NL2007536C2 (en) * | 2011-10-05 | 2013-04-08 | Academisch Ziekenhuis Leiden Lumc | Adjuvant compound. |
EP2822589A1 (en) | 2012-03-07 | 2015-01-14 | Novartis AG | Adjuvanted formulations of rabies virus immunogens |
WO2013131983A1 (en) | 2012-03-07 | 2013-09-12 | Novartis Ag | Adjuvanted formulations of streptococcus pneumoniae antigens |
JP6345603B2 (ja) | 2012-03-08 | 2018-06-20 | ノバルティス アーゲー | 追加免疫ワクチンのアジュバント化された処方物 |
US8782263B1 (en) * | 2012-04-20 | 2014-07-15 | Disney Enterprises, Inc. | Authenticated session controller |
CN103570809B (zh) * | 2012-07-20 | 2015-06-24 | 华东师范大学 | 一种抗炎症的脂肽及其制备方法和应用 |
JP6324961B2 (ja) | 2012-09-06 | 2018-05-16 | ノバルティス アーゲー | 血清群b髄膜炎菌とd/t/pとの組み合わせワクチン |
WO2014113634A1 (en) * | 2013-01-17 | 2014-07-24 | University Of Kansas | Toll-like receptor 2-agonistic lipopeptides, and method of making the same |
WO2014118305A1 (en) | 2013-02-01 | 2014-08-07 | Novartis Ag | Intradermal delivery of immunological compositions comprising toll-like receptor agonists |
SG11201509265SA (en) | 2013-05-10 | 2015-12-30 | Novartis Ag | Avoiding narcolepsy risk in influenza vaccines |
CN104338129B (zh) * | 2013-07-26 | 2017-05-24 | 中国科学院上海巴斯德研究所 | 雷帕霉素作为疫苗佐剂的用途及制备方法 |
WO2015065168A1 (en) * | 2013-10-28 | 2015-05-07 | Universiti Malaya | Oligo-ethylene glycol based phosphonate surface modification reagents and use thereof |
EP3087054A4 (en) | 2013-12-27 | 2017-10-25 | Novus International Inc. | Ethoxylated surfactants |
AU2017290238B2 (en) * | 2016-06-29 | 2021-02-18 | The Board Of Regents Of The University Of Texas System | Diprovocims: a new and potent class of TLR agonists |
AU2018241248A1 (en) * | 2017-03-31 | 2019-09-05 | Ena Respiratory Pty Ltd | Treatment of respiratory infection with a TLR2 agonist |
US10584306B2 (en) | 2017-08-11 | 2020-03-10 | Board Of Regents Of The University Of Oklahoma | Surfactant microemulsions |
BR112020012360A2 (pt) * | 2017-12-21 | 2020-11-24 | Ena Therapeutics Pty Ltd | compostos otimizados |
RU2703264C1 (ru) * | 2018-05-30 | 2019-10-16 | Татьяна Борисовна Корженевская | Способ лечения катаральных осложнений верхних дыхательных путей при острых респираторных вирусных инфекциях у детей |
WO2020023872A1 (en) * | 2018-07-27 | 2020-01-30 | Children's Medical Center Corporation | Use of toll-like receptor 2 (tlr-2) agonist for modulating human immune response |
CN109758467B (zh) * | 2019-03-08 | 2020-12-25 | 中国农业科学院兰州兽医研究所 | 一种吉西他滨在制备预防口蹄疫病毒感染的药物中的应用 |
AU2020302839A1 (en) * | 2019-06-26 | 2022-01-20 | Ena Respiratory Pty Ltd | Novel molecules |
CN110742880A (zh) * | 2019-10-24 | 2020-02-04 | 上海长海医院 | Cl419在制备治疗炎性肠病药物中的用途 |
CA3161668A1 (en) | 2019-12-20 | 2021-06-24 | Nammi Therapeutics, Inc. | Formulated and/or co-formulated liposome compositions containing toll-like receptor ("tlr") agonist prodrugs useful in the treatment of cancer and methods thereof |
WO2021207155A1 (en) * | 2020-04-06 | 2021-10-14 | The Trustees Of Indiana University | Airway epithelial alkaline therapy to treat viral respiratory infection |
WO2021258154A1 (en) * | 2020-06-26 | 2021-12-30 | Axelia Oncology Pty Ltd | Branched lipid compounds |
WO2023141470A2 (en) * | 2022-01-19 | 2023-07-27 | President And Fellows Of Harvard College | Immunomodulatory lipids and uses thereof |
WO2023229891A1 (en) * | 2022-05-25 | 2023-11-30 | Ayuvis Research, Inc. | Novel immunodulating small molecules |
Family Cites Families (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2848965A1 (de) | 1978-11-11 | 1980-05-22 | Behringwerke Ag | Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine |
EP0114787B1 (de) * | 1983-01-25 | 1991-09-25 | Ciba-Geigy Ag | Neue Peptidderivate |
DE3546150A1 (de) * | 1985-06-24 | 1987-01-22 | Hoechst Ag | Membrananker-wirkstoffkonjugat, seine herstellung sowie seine verwendung |
DE3813821A1 (de) | 1988-04-22 | 1989-11-02 | Hoechst Ag | Synthetische vakzine gegen die maul- und klauenseuche und verfahren zu deren herstellung |
DE3937412A1 (de) | 1989-11-10 | 1991-05-16 | Hoechst Ag | Synthetische vakzine zur spezifischen induktion zytotoxischer t-lymphozyten |
DE4116256C2 (de) * | 1991-05-17 | 1996-08-29 | Max Planck Gesellschaft | Bestimmung von Peptidmotiven auf MHC-Molekülen |
EP0547681A2 (en) | 1991-12-18 | 1993-06-23 | Merck & Co. Inc. | Synthetic peptides comprising a cyclic HIV principal neutralizing determinant and a lipopeptide |
DK0548024T3 (da) * | 1991-12-19 | 1997-01-27 | Ciba Geigy Ag | Aminosulfonsyrederivater samt fremgangsmåder til deres fremstilling |
AU666789B2 (en) * | 1992-12-28 | 1996-02-22 | Takeda Chemical Industries Ltd. | 2-amino-6,7-dihydroxy-4-thiaheptanoic acid derivatives, production and use thereof |
JPH07145084A (ja) * | 1992-12-28 | 1995-06-06 | Takeda Chem Ind Ltd | Tan−1511関連化合物 |
EP0604945A1 (en) | 1992-12-28 | 1994-07-06 | Takeda Chemical Industries, Ltd. | TAN-1511, its derivatives, production and use thereof |
JPH07126243A (ja) * | 1993-09-10 | 1995-05-16 | Takeda Chem Ind Ltd | チオグリセロール誘導体 |
IL117483A (en) | 1995-03-17 | 2008-03-20 | Bernard Brodeur | MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K. |
US6180111B1 (en) | 1995-05-18 | 2001-01-30 | University Of Maryland | Vaccine delivery system |
EP0907738A1 (en) | 1996-04-02 | 1999-04-14 | Smithkline Beecham Corporation | Novel compounds |
WO1997043304A1 (en) | 1996-05-14 | 1997-11-20 | Smithkline Beecham Corporation | Novel compounds |
EP1770164B1 (en) | 1996-10-31 | 2010-09-01 | Human Genome Sciences, Inc. | Streptococcus pneumoniae antigens and vaccines |
GB9711964D0 (en) | 1997-06-09 | 1997-08-06 | Medical Res Council | Live attenuated vaccines |
US6800744B1 (en) | 1997-07-02 | 2004-10-05 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics |
ES2301181T3 (es) | 1997-08-21 | 2008-06-16 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Mutantes nuevos de bacterias mucosas gram negativas y su aplicacion en vacunas. |
EP1900818A3 (en) | 1997-11-06 | 2008-06-11 | Novartis Vaccines and Diagnostics S.r.l. | Neisserial antigens |
JP4486748B2 (ja) | 1997-11-26 | 2010-06-23 | インヒビテツクス,インコーポレイテツド | 黄色ブドウ球菌由来の細胞外マトリックス結合タンパク質 |
CA2317815A1 (en) | 1998-01-14 | 1999-07-22 | Chiron S.P.A. | Neisseria meningitidis antigens |
CA2328399A1 (en) | 1998-04-23 | 1999-10-28 | University Of Alabama At Birmingham | Pneumococcal surface protein c(pspc), epitopic regions and strain selection thereof, and uses therefor |
EP2261343A3 (en) | 1998-05-01 | 2012-01-18 | Novartis Vaccines and Diagnostics, Inc. | Neisseria meningitidis antigens and compositions |
GB9810193D0 (en) | 1998-05-12 | 1998-07-08 | Smithkline Beecham Biolog | Novel compounds |
JP2002531055A (ja) | 1998-07-27 | 2002-09-24 | マイクロビアル テクニクス リミティッド | 肺炎連鎖球菌のタンパク質及び核酸分子 |
CN1318103A (zh) | 1998-07-27 | 2001-10-17 | 微生物技术有限公司 | 肺炎链球菌的核酸和蛋白质 |
KR100871330B1 (ko) | 1998-08-31 | 2008-12-01 | 더 프로보스트 펠로우스 앤드 스콜라스 오브 더 칼리지 오브 더 홀리 앤드 언디바이디드 트리니티 오브 퀸 엘리자베스 니어 더블린 | 응고효소 음성 포도상구균 유래의 폴리펩타이드 및폴리뉴클레오타이드 |
KR100644953B1 (ko) | 1998-08-31 | 2006-11-10 | 인히비텍스, 인코포레이티드 | 다성분 백신 |
JP2004511201A (ja) | 1998-10-09 | 2004-04-15 | カイロン コーポレイション | ナイセリアゲノム配列およびそれらの使用方法 |
GB9823978D0 (en) | 1998-11-02 | 1998-12-30 | Microbiological Res Authority | Multicomponent meningococcal vaccine |
GB9828000D0 (en) | 1998-12-18 | 1999-02-10 | Chiron Spa | Antigens |
WO2000037105A2 (en) | 1998-12-21 | 2000-06-29 | Medimmune, Inc. | Streptococcus pneumoniae proteins and immunogenic fragments for vaccines |
CN1198932C (zh) | 1999-03-26 | 2005-04-27 | 科特克斯(Om)有限公司 | 肺炎链球菌抗原 |
JP2003501110A (ja) | 1999-06-10 | 2003-01-14 | メディミューン,インコーポレーテッド | 肺炎連鎖球菌タンパク質とワクチン |
EP1075841A1 (en) | 1999-08-13 | 2001-02-14 | Erasmus Universiteit Rotterdam | Pneumococcal vaccines |
WO2001034642A2 (en) | 1999-11-12 | 2001-05-17 | University Of Iowa Research Foundation | Control of neisserial membrane synthesis |
DK2289545T3 (en) | 2000-01-17 | 2016-09-05 | Glaxosmithkline Biologicals Sa | Supplemented OMV vaccine against meningococcus |
PT2270030E (pt) | 2000-02-28 | 2012-07-24 | Novartis Vaccines & Diagnostic | Expressão heteróloga de proteínas de neisseria |
JP4852211B2 (ja) | 2000-03-21 | 2012-01-11 | メルク アンド カンパニー インコーポレイテッド | 原核生物における必須遺伝子の同定 |
EP1278856A2 (en) | 2000-04-27 | 2003-01-29 | Medimmune, Inc. | Immunogenic pneumococcal protein and vaccine compositions thereof |
NO20002828D0 (no) | 2000-06-02 | 2000-06-02 | Statens Inst For Folkehelse | Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav |
US6495079B1 (en) | 2000-06-28 | 2002-12-17 | Prisma Fibers, Inc. | Process to prepare polymeric fibers with improved color and appearance |
EP1297005B1 (en) | 2000-07-03 | 2009-08-26 | Novartis Vaccines and Diagnostics S.r.l. | Immunisation against chlamydia pneumoniae |
AU2001287645A1 (en) | 2000-07-20 | 2002-02-05 | Hansa Medical Ab | Fh-binding protein of streptococcus pneumiae |
KR20030024811A (ko) | 2000-07-27 | 2003-03-26 | 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 | 나이세리아 메닌지티디스에 의하여 유발되는 질병에 대한광범위하게 유효한 보호를 위한 백신 |
GB0103170D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
AU8743001A (en) | 2000-08-28 | 2002-03-13 | Aventis Pasteur | Moraxella polypeptides and corresponding dna fragments and uses thereof |
GB0022742D0 (en) | 2000-09-15 | 2000-11-01 | Smithkline Beecham Biolog | Vaccine |
AU2001295795A1 (en) | 2000-10-26 | 2002-05-06 | Imperial College Innovations Ltd. | Streptococcal genes |
MXPA03003690A (es) | 2000-10-27 | 2004-05-05 | Chiron Spa | Acidos nucleicos y proteinas de los grupos a y b de estreptococos. |
AT410798B (de) | 2001-01-26 | 2003-07-25 | Cistem Biotechnologies Gmbh | Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen |
GB0103171D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
GB0103424D0 (en) | 2001-02-12 | 2001-03-28 | Chiron Spa | Gonococcus proteins |
WO2002077183A2 (en) | 2001-03-21 | 2002-10-03 | Elitra Pharmaceuticals, Inc. | Identification of essential genes in microorganisms |
GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
GB0108079D0 (en) | 2001-03-30 | 2001-05-23 | Microbial Technics Ltd | Protein |
EP1399181B1 (en) | 2001-05-18 | 2012-05-09 | The Government of the USA, as represented by the Secretary, Dept. of Health and Human Services, Centers for Disease Control and Prevention | Peptide vaccines against group a streptococci |
WO2002102829A2 (en) | 2001-06-15 | 2002-12-27 | Inhibitex, Inc. | Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus |
GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
ATE542829T1 (de) | 2001-08-02 | 2012-02-15 | Univ Sheffield | Impfstoff |
DE60228758D1 (de) | 2001-12-12 | 2008-10-16 | Novartis Vaccines & Diagnostic | Immunisierung gegen chlamydia tracheomatis |
GB0203403D0 (en) | 2002-02-13 | 2002-04-03 | Chiron Spa | Chlamydia cytotoxic-T cell epitopes |
IL164242A0 (en) | 2002-04-02 | 2005-12-18 | Univ Ben Gurion | Protein-based streptococcus pneumoniae vaccines |
GB0210128D0 (en) | 2002-05-02 | 2002-06-12 | Chiron Spa | Nucleic acids and proteins from streptococcus groups A & B |
CN100360558C (zh) | 2002-06-11 | 2008-01-09 | 葛兰素史密丝克莱恩生物有限公司 | 免疫原性组合物 |
GB0213622D0 (en) | 2002-06-13 | 2002-07-24 | Glaxosmithkline Biolog Sa | Vaccine Corporation |
EP1382352A1 (de) * | 2002-07-19 | 2004-01-21 | GBF Gesellschaft für Biotechnologische Forschung mbH | Bisacyloxypropylcystein-Konjugate und deren Verwendung |
KR101239242B1 (ko) | 2002-08-02 | 2013-03-11 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 항원 조합물을 포함하는 나이세리아 백신 조성물 |
EP2314630A1 (en) * | 2002-08-12 | 2011-04-27 | The Council Of The Queensland Institute Of Medical Research | Method of producing immunogenic lipopeptides comprising T-helper and Cytotoxic T Lymphocyte (CTL) epitopes |
GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
ES2504166T3 (es) | 2002-09-13 | 2014-10-08 | Novartis Vaccines And Diagnostics, Inc. | Vacuna de estreptococo del grupo B |
AU2003274511B2 (en) | 2002-10-11 | 2009-06-04 | Glaxosmithkline Biologicals S.A. | Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages |
WO2004045641A2 (en) * | 2002-11-20 | 2004-06-03 | Crucell Holland B.V. | Antigen-complexes |
US7491395B2 (en) * | 2002-11-20 | 2009-02-17 | Bestewil Holding B.V. | Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
US20060257852A1 (en) | 2003-04-10 | 2006-11-16 | Chiron Corporation | Severe acute respiratory syndrome coronavirus |
WO2004092209A2 (en) | 2003-04-15 | 2004-10-28 | Intercell Ag | S. pneumoniae antigens |
AR056245A1 (es) * | 2003-06-19 | 2007-10-03 | Bestewil Holding Bv | Membranas virales reconstituidas funcionales que contienen un coadyuvante |
EP1635865A2 (en) | 2003-06-26 | 2006-03-22 | Chiron Corporation | Immunogenic compositions for chlamydia trachomatis |
GB0316560D0 (en) | 2003-07-15 | 2003-08-20 | Chiron Srl | Vesicle filtration |
ES2505695T3 (es) | 2003-07-31 | 2014-10-10 | Novartis Vaccines And Diagnostics, Inc. | Composiciones inmunógenas para Streptococcus pyogenes |
AU2005214061B2 (en) | 2004-02-18 | 2010-02-04 | Merck Sharp & Dohme Corp. | Polypeptides for inducing a protective immune response against Staphylococcus aureus |
GB0419627D0 (en) | 2004-09-03 | 2004-10-06 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
ES2540770T3 (es) | 2004-09-22 | 2015-07-13 | Glaxosmithkline Biologicals Sa | Composición inmunógena para uso en vacunación contra estafilococos |
CA2590974C (en) | 2005-01-27 | 2017-10-03 | Children's Hospital & Research Center At Oakland | Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
AU2006216822A1 (en) * | 2005-02-22 | 2006-08-31 | Daniel Rachmilewitz | Methods of treating gastrointestinal inflammation |
EP2316483A1 (en) * | 2005-12-01 | 2011-05-04 | The Provost Fellows And Scholars Of The College Of The Holy and Undivided Trinity Of Queen Elizabeth Near Dublin | Compositions and methods relating to the treatment of cancer and infectious diseases |
EP2390372A1 (en) | 2005-12-27 | 2011-11-30 | Obetech, LLC | Vaccination against adipogenic adenoviruses. |
WO2007079448A2 (en) * | 2006-01-03 | 2007-07-12 | University Of Georgia Research Foundation, Inc. | Three component carbohydrate vaccine |
CA2637598A1 (en) | 2006-01-18 | 2007-02-14 | University Of Chicago | Compositions and methods related to staphylococcal bacterium proteins |
EP1994047A2 (en) | 2006-02-17 | 2008-11-26 | Novartis AG | Purification and use of streptococcus pneumoniae pili and pilus proteins |
AR060187A1 (es) | 2006-03-30 | 2008-05-28 | Glaxosmithkline Biolog Sa | Composicion inmunogenica |
EA020459B1 (ru) | 2006-03-30 | 2014-11-28 | Глаксосмитклайн Байолоджикалс С.А. | Иммуногенная композиция |
EP2050455B1 (en) * | 2007-10-18 | 2012-08-01 | DC Gesellschaft für dentritic-cell-Therapie mbH | Compounds leading to an increase of the IL-12/IL-10 ratio and their use for therapy of infectious and proliferative diseases |
WO2009108762A2 (en) * | 2008-02-26 | 2009-09-03 | The Penn State Research Foundation | Methods and compositions for treatment of retinoid-responsive conditions |
GB0907989D0 (en) | 2009-05-08 | 2009-06-24 | Hybrid Systems Ltd | Multivalent adjuvant display |
US20120177681A1 (en) * | 2010-09-01 | 2012-07-12 | Manmohan Singh | Formulation of immunopotentiators |
-
2011
- 2011-03-23 KR KR1020127027449A patent/KR101853513B1/ko active IP Right Grant
- 2011-03-23 WO PCT/US2011/029661 patent/WO2011119759A1/en active Application Filing
- 2011-03-23 EA EA201201321A patent/EA023725B1/ru not_active IP Right Cessation
- 2011-03-23 JP JP2013501437A patent/JP5848748B2/ja not_active Expired - Fee Related
- 2011-03-23 MX MX2012010968A patent/MX341395B/es active IP Right Grant
- 2011-03-23 CA CA2792938A patent/CA2792938C/en not_active Expired - Fee Related
- 2011-03-23 US US13/636,328 patent/US8808703B2/en active Active
- 2011-03-23 EP EP11715325A patent/EP2549990A1/en not_active Withdrawn
- 2011-03-23 AU AU2011232421A patent/AU2011232421B2/en not_active Ceased
- 2011-03-23 EA EA201501033A patent/EA031379B1/ru not_active IP Right Cessation
- 2011-03-23 CN CN201180025589.5A patent/CN102905703B/zh not_active Expired - Fee Related
-
2014
- 2014-07-09 US US14/326,957 patent/US9365506B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US9365506B2 (en) | 2016-06-14 |
EP2549990A1 (en) | 2013-01-30 |
EA023725B1 (ru) | 2016-07-29 |
CA2792938A1 (en) | 2011-09-29 |
AU2011232421B2 (en) | 2015-08-13 |
MX2012010968A (es) | 2012-11-23 |
CN102905703B (zh) | 2016-09-28 |
US20140323390A1 (en) | 2014-10-30 |
US20130065861A1 (en) | 2013-03-14 |
AU2011232421A1 (en) | 2012-10-25 |
EA031379B1 (ru) | 2018-12-28 |
KR20130012068A (ko) | 2013-01-31 |
CA2792938C (en) | 2018-07-31 |
EA201501033A1 (ru) | 2016-06-30 |
JP5848748B2 (ja) | 2016-01-27 |
US8808703B2 (en) | 2014-08-19 |
KR101853513B1 (ko) | 2018-04-30 |
CN102905703A (zh) | 2013-01-30 |
JP2013527142A (ja) | 2013-06-27 |
WO2011119759A1 (en) | 2011-09-29 |
MX341395B (es) | 2016-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201501033A1 (ru) | Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний | |
PH12019550050A1 (en) | Isoxazole analogs as fxr agonists and methods of use thereof | |
EA201491548A1 (ru) | 2'-замещенные карбануклеозидные аналоги для противовирусного лечения | |
EA201270356A1 (ru) | Иммуногенные композиции, содержащие модуляторы активности tlr | |
IN2012DN02736A (ru) | ||
EA201692506A3 (ru) | Ингибиторы репликации вирусов гриппа | |
CO7170160A2 (es) | Nuevas 6-aminoacido-heteroarildihidropirimidinas para el tratamiento y profilaxis de la infección del virus de la hepatitis b | |
BR112015022197A8 (pt) | uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia | |
BR112013003772A2 (pt) | composições de compostos modificadores de resposta imunológica lipidadas, formulações e métodos | |
MX2015012397A (es) | Composiciones y metodos basados en anticuerpos neutralizados suministrados intranasalmente para eficacia terapeutica aumentada. | |
EA201500383A1 (ru) | Производные 1,2,4-триазина для лечения вирусных инфекций | |
EA201391515A1 (ru) | Инактивированная вакцина вируса денге | |
EA201500851A1 (ru) | ЭСТРА-1,3,5(10),16-ТЕТРАЕН-3-КАРБОКСАМИДЫ ДЛЯ ИНГИБИРОВАНИЯ 17β-ГИДРОКСИСТЕРОИД-ДЕГИДРОГЕНАЗЫ (AKR1C3) | |
EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
EA201491500A1 (ru) | Способы лечения фиброза | |
GB2539148A (en) | Vaccine compositions | |
EA201791432A1 (ru) | Композиции на основе пролекарства монометилфумарата | |
EA201490573A1 (ru) | Соединение бензотиазолона | |
MX2019012375A (es) | Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1). | |
EA201690966A1 (ru) | Новое соединение для лечения тяжелой гипогликемии | |
BR112013023354A2 (pt) | vacina para rinite equina | |
EA201501177A1 (ru) | Фармацевтические композиции | |
EA201690673A1 (ru) | Комбинированная терапия лахинимодом для лечения рассеянного склероза | |
PL409016A1 (pl) | N-sulfonowa pochodna polialliloaminy, zastosowanie N-sulfonowej pochodnej polialliloaminy jako leku, zwłaszcza do profilaktyki i leczenia infekcji wirusem grypy typu A (IAV) oraz kompozycja farmaceutyczna zawierająca N-sulfonową pochodną polialliloaminy | |
TN2013000150A1 (en) | Co-crystals and salts of ccr3-inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |